Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

BHV-7000

Small molecule · developed by Biohaven

Phase 2/3 Most advanced trial

BHVN Developer

1 Registered trials

What is BHV-7000?

BHV-7000 is an investigational small-molecule drug studied in Focal Epilepsy.

At a glance

Drug type: Small molecule
Therapy area: Neurology
Developer: Biohaven (BHVN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII: 73H9J7RBA2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06309966	Phase 2/3	Focal Epilepsy	Active not recruiting	BHVN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Focal Epilepsy

More from Biohaven

BHV-1300 Phase 3 BHV-1400 Phase 3 BHV-1530 Phase 1 BHV-2100 Phase 2 BHV-700 Phase 1 BHV-8000 Phase 2/3 PBI-410 Phase 1/2 Talditercept Alfa Phase 3 Troriluzole Phase 3 Verdiperstat Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BHVN page.

Follow BHVN, the company behind BHV-7000

See BHVN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BHVN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z